<DOC>
	<DOCNO>NCT01337583</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled Phase III study ass safety efficacy silicone elastomer vaginal ring contain 25mg dapivirine .</brief_summary>
	<brief_title>A Safety Efficacy Trial Dapivirine Vaginal Ring Africa</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women &gt; 18 &lt; 40 year age provide inform consent Available visit consent follow procedure schedule trial Generally healthy selfreported sexually active ( defined average least one penetrative penile vaginal coital act per month last 3 month prior enrolment ) HIVnegative determine HIV algorithm apply screen enrolment On stable form contraception willing continue stable contraception duration clinical trial ; Asymptomatic genital infection time enrolment ( woman diagnose clinically significant treatable STI , must initiate treatment least 1 week prior enrolment complete full course treatment ) Willing answer question adherence , sexual behaviour , vaginal practice ring acceptability ; Willing provide adequate locator information trial retention purpose reachable per local standard procedure ( e.g. , home visit telephone ; via family close neighbour contact [ confidentiality maintain ] ) Willing refrain participation another research trial use drug , vaccine , medical device , microbicides oral preexposure prophylaxis investigational drug duration IPM 009B trial ; In absence use exogenous hormone ( ) , selfreported regular menstrual cycle define minimum 21 day maximum 35 day menses ; Willing refrain use vaginal product object include spermicide , tampon , female condom , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche dry agent within 14 day enrolment duration trial . Currently pregnant last pregnancy within 3 month prior screen ; Currently breastfeed Participated another research trial use drug , medical device , microbicides oral preexposure prophylaxis agent within 60 day prior screen Previously participate currently participate HIV vaccine trial Untreated , clinically significant urogenital infection ( either symptomatic asymptomatic ) , e.g. , urinary tract sexually transmitted infection , gynaecological symptom within 1 week prior enrolment History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence Any gynaecological surgery within 90 day prior enrolment Any Grade 3 4 baseline haematology , chemistry urinalysis laboratory value accord DAIDS Table Grading Adverse Experiences , clinically significant Grade 2 finding Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone elastomer Any history diabetes mellitus chronic use oral steroid therapy uncontrolled serious chronic progressive disease Cervical cytology screen require cryotherapy , biopsy , treatment ( infection ) , evaluation [ include finding atypical squamous cell undetermined significance ( ASCUS ) ] Any condition ( ) , opinion investigator , might put participant risk , interfere trial objective , adherence trial requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Anti-HIV agent</keyword>
	<keyword>HIV-1</keyword>
</DOC>